Imaging Technology

JUNE 10, 2024

The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto. More recently, she and her collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, recently approved for human studies by the FDA as an Investigational New Drug.

Nuclear Medicine 79

Nuclear Medicine Radiopharmaceuticals Disease Imaging 79

Diagnostic Imaging

JUNE 9, 2024

shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnostic radiopharmaceuticals to increasing patient interest in PET imaging. In a recent interview, Cathy Cutler, Ph.D.,

Nuclear Medicine 68

Nuclear Medicine Radiopharmaceuticals Diagnostic Imaging 68

Open Medscience

AUGUST 8, 2019

Imaging agents can be used to evaluate organ function, detect cancer, measure blood flow and follow metabolic processes. The post Radiometals for diagnostic imaging and theranostics appeared first on Open Medscience.

Diagnostic Imaging 52

Diagnostic Imaging Diagnostic Imaging Radiopharmaceuticals 52

Imaging Technology

APRIL 3, 2023

produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.

Medical 78

Medical Radiopharmaceuticals Pharmaceutical Radiation 78

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 Blue Earth Diagnostics received U.S.

Clinic 78

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 78

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Open Medscience

JUNE 22, 2024

Radiotheranostic Pairs combine diagnostic imaging with targeted radiotherapy, revolutionising personalised cancer treatment through enhanced precision and efficacy. The post Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer appeared first on Open MedScience.

Diagnostic 52

Diagnostic Diagnostic Imaging Imaging Radiopharmaceuticals 52

TTG Imaging Solutions

FEBRUARY 17, 2022

About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnostic imaging, and radiopharmaceuticals.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging 52

Future Teleradiology

NOVEMBER 27, 2023

Discuss how these advancements enhance imaging capabilities, providing clearer insights into physiological processes. Discuss how theranostic approaches integrate diagnostic imaging and targeted therapy for more personalized and effective treatments.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Imaging Modalities Radiation 52

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

TTG Imaging Solutions

JANUARY 9, 2022

About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnostic imaging, and radiopharmaceuticals.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Imaging Diagnostic Imaging 52

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.

Nuclear Medicine 40

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging 40

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.

Nuclear Medicine 40

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging 40

TTG Imaging Solutions

OCTOBER 20, 2021

About TTG Imaging Solutions TTG Imaging Solutions is your partner for nationwide equipment sales, service, parts, turnkey diagnostic imaging, and radiopharmaceuticals. Request a meeting with one of our Regional Sales Managers at sales@ttgimagingsolutions.com.

Radiation Oncology 52

Radiation Oncology Imaging Radiopharmaceuticals Radiation 52

TTG Imaging Solutions

SEPTEMBER 28, 2021

About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnostic imaging, and radiopharmaceuticals.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging 52

TTG Imaging Solutions

OCTOBER 27, 2021

About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnostic imaging, and radiopharmaceuticals.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging 52

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Blue Earth Diagnostics received U.S.

Diagnostic 72

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 72

TTG Imaging Solutions

MAY 5, 2023

Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.

Imaging 52

Imaging Radiopharmaceuticals Radiation Oncology Nuclear Medicine 52

Future Teleradiology

NOVEMBER 21, 2023

Discuss how PET/CT and PET/MRI combinations offer superior imaging capabilities, providing both anatomical and functional information in a single examination. Advancements in Radiopharmaceuticals: Precision Imaging Agents: Discuss the latest developments in radiopharmaceuticals.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Teleradiology 52

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Gauden , D.Phil., 18F-rhPSMA-7.3

Diagnostic 89

Diagnostic Radiopharmaceuticals Imaging Radiation 89

Imaging Technology

JULY 28, 2023

Precision PET imaging with POSLUMA can help identify the location and extent of prostate cancer, providing clinically valuable information to guide patient management. Blue Earth Diagnostics received U.S. Food and Drug Administration approval for its radiohybrid PET diagnostic imaging product for use in prostate cancer in 2023.

Clinic 81

Clinic Diagnostic Radiopharmaceuticals Radiation 81

Imaging Technology

JUNE 20, 2024

More than half of the world’s population is underserved and lacks access to essential health services, and two-thirds have no access to diagnostic imaging. Product life extension & upgrades GE HealthCare is also proud to offer global refurbished medical equipment, helping to improve access to affordable, quality healthcare.

Healthcare 77

Healthcare Healthcare Nuclear Medicine Computed Tomography 77

TTG Imaging Solutions

NOVEMBER 1, 2021

The organization brought a robust customer base in the mid-west along with a strong group of field service engineers The following executive leadership changes are effective November 1, 2021: Jack Tomayko, Ph.D., Remaining in their current roles are John Nalley, EVP of Equipment Service Operations, and Hunter Forestier, VP of Sales and Marketing.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Medical Imaging 52

Imaging Technology

OCTOBER 5, 2023

Nationally recognized clinical oncology guidelines for prostate cancer now include POSLUMA, alongside and for all the same categories as the other currently FDA-approved PSMA PET radiopharmaceuticals.” PET in Men with Newly Diagnosed High-risk Prostate Cancer and Negative Conventional Imaging, ” by Phillip H.

Diagnose 52

Diagnose Diagnostic Disease Radiation 52